Waters Corporation

- There is no explicit mention of new fundraising through debt or equity in the provided pages. - Net interest expense for the year is expected to be approximately $186 million, indicating existing debt servicing but no new debt issuance announced. - The company discusses operational improvements, synergy realization, and cost management rather than capital raising. - No reference to new equity issuance or planned fundraising activities. - Free cash flow was $42 million in Q1, affected by deal-related costs, implying reliance on existing funds. - Overall focus is on growth, revenue synergies, and margin expansion without highlighted capital raise plans.

- Localization of manufacturing in China for Flow cytometry instruments to improve market access and reduce export complexity, starting in Q3 2026 (Page 3). - Investment in new product launches such as next-generation Microflow LC Chemistry Columns with MaxPeak Premier technology and omniDAWN Multi Angle Light Scattering Detector (Page 3). - Launch of next-generation BACTEC FXI blood culture system with CE marking, with ongoing regulatory approvals in key markets (Page 3). - Continuous investments in R&D, with 70%-80% dedicated to bioseparations (Page 11). - Operational improvements under the 180-day plan including increased commercial activity, pricing initiatives, and funnel reviews (Page 3). - Cost synergies and broader cost actions expected to enhance margins but no specific capital expenditure figures given (Page 5).

- The company expects total reported 2026 revenue of approximately $6.405 billion to $6.455 billion, including $35 million of revenue synergies from acquired businesses. - Organic constant currency revenue growth guidance for full year 2026 is raised to 6.5% to 8%, reflecting strong Q1 performance and $15 million expected revenue synergy contribution. - Second quarter 2026 organic constant currency revenue growth is expected at 6% to 8%, with reported revenues guided at $814 million to $829 million. - Second half of 2026 organic growth is prudently modeled at ~6%, derisking outlook due to macro factors and fewer working days. - Acquired Biosciences and Diagnostic Solutions businesses are expected to generate roughly $3.035 billion revenue in 2026 with ongoing commercial and operational initiatives driving growth. - Pricing discipline, localization efforts (especially in China), and new product launches (e.g., BACTEC FXI) are key growth drivers. - Long term aims include mid-to-high single-digit organic growth, increasing synergies, and margin expansion.

- Full-year 2026 adjusted EBIT margin expected at 28.2%, reflecting strong first quarter results and cost synergy actions starting in Q3. - Adjusted earnings per fully diluted share (EPS) guidance raised to $14.40–$14.60 for 2026, up $0.10 from prior, reflecting strong Q1 performance and updated FX rates. - Second quarter adjusted EPS expected in range $2.95 to $3.05, flat to 3.4% growth, despite higher interest costs and shares issued; cost synergies to start benefiting P&L from Q3. - Mid-teens adjusted EPS growth algorithm targeted over the next several years, driven by operational improvements, innovation, and synergy realization. - Organic constant currency revenue growth guidance raised to 6.5% to 8% for 2026, with continued momentum and $15 million revenue synergies embedded. - Executives expect at least 100 basis points adjusted operating margin expansion annually through decade-end.

- The company reports very strong orderbook and funnel visibility, described as "better than they ever have" (Page 9). - Forecast accuracy has improved due to enhanced collaboration and integration efforts post-acquisition (Page 9). - The 180-day growth revitalization plan has increased commercial activity, leading to stronger funnel trends and overall momentum (Page 3). - Pricing initiatives and deal desks are being implemented, enhancing revenue potential but not yet fully reflected in guidance (Page 12). - Continued strong demand in key segments like LCMS instruments, chemistry, and service, with sustained instrument replacement cycles giving a good runway into 2027 (Page 13). - Despite macro uncertainties, the company expresses high confidence in the strength of the funnel and orderbook for the remainder of the year (Pages 10 and 13).